the group of substituents, R^c, consists of a halogen atom, a hydroxy group, a cyano group, a nitro group, an amino group (the amino group may be substituted with a C_{2-6} alkanoyl group or one or two C_{1-6} alkyl groups), a carboxy group, a carbamoyl group, a ureido group, a guanidido group, a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with a heterocyclic group), a C_{1-6} hydroxyalkyl group, a C_{1-6} haloalkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (the C_{1-6} alkoxy group may be substituted with 1 to 3 hydroxy groups), a C_{3-8} cycloalkoxy group, a C_{1-6} alkoxycarbonyl group, a C_{1-6} alkoxycarbonylamino group, a C_{2-6} alkanoyl group, a C_{1-6} alkylsulfonyl group, a C_{1-6} alkylthio group, an aryl group, and a heterocyclic group (the aryl group and the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, a cyano group, a nitro group, an amino group, a carboxy group and a C_{1-6} alkyl group").

3. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein R^1 is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with the same or different 1 to 3 halogen atoms).

4. The compound or the pharmaceutically acceptable salt thereof, according to claim 3, wherein R^1 is a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with the same or different 1 to 3 halogen atoms).

5. The compound or the pharmaceutically acceptable salt thereof, according to claim 4, wherein R^1 is a methyl group.

6. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 5, wherein R^2 is a hydrogen atom.

7. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 5, wherein R^2 is a methyl group.

8. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, wherein

R^3 is a hydrogen atom, and

R^4 is a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with a phenyl group

or a monocyclic aromatic heterocyclic group (the phenyl group and the monocyclic aromatic heterocyclic group may be substituted with 1 to 3 substituents which are the same or different and are selected from "a halogen atom, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} haloalkyl group, a C_{1-6} hydroxyalkyl group, a C_{2-8} alkoxyalkyl group, a hydroxy group, a C_{1-6} alkoxy group, a C_{3-8} cycloalkoxy group, an amino group, a C_{1-6} alkylamino group, a di(C_{1-6} alkyl)amino group, $-N(R^{45})COR^{46}$, $-CON(R^{47})(R^{48})$")).

9. The compound or the pharmaceutically acceptable salt thereof, according to claim 8, wherein R^3 is a hydrogen atom, and R^4 is a methyl group.

10. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9, wherein A^1 is a phenylene group (the phenylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group").

11. The compound or the pharmaceutically acceptable salt thereof, according to claim 10, wherein A^1 is a phenylene group.

12. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 11, wherein L is -C≡C-, -C≡C-C≡C-, -CH=CH-, -CH=CH-C≡C-, -C≡C-CH=CH-, an ethylene group, or a bond.

13. The compound or the pharmaceutically acceptable salt thereof, according to claim 12, wherein L is a bond or -C≡C-.

14. The compound or the pharmaceutically acceptable salt thereof, according to claim 13, wherein L is a bond.

15. The compound or the pharmaceutically acceptable salt thereof, according to claim 13, wherein L is -C≡C-.

16. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 15, wherein

A^2 is a divalent aryl group (the divalent aryl group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group"), a divalent monocyclic aromatic

fused ring heterocyclic group having a partially saturated monocycle, which is composed of a 5-membered ring and a 6-membered ring" (the phenylene group, the pyridinediyl group, the pyrimidinediyl group, the 2,4-furandiyl group, the pyrazolediyl group, the pyrrolediyl group, the "divalent fused ring aromatic heterocyclic group composed of a 5-membered ring and a 6-membered ring", and the "divalent fused ring heterocyclic group having a partially saturated monocycle, which is composed of a 5-membered ring and a 6-membered ring" may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group").

19. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 18, wherein

W is R^6-X^1-,

X^1 is a methylene group or a bond,

R^6 is a hydrogen atom, an optionally protected hydroxy group, or R^8-ON=CR^9-,

R^8 is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below),

R^9 is a hydrogen atom, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, an amino group, or a C_{1-6} alkylamino group, and

the group of substituents, R^c, consists of a halogen atom and a hydroxy group.

20. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 18, wherein

W is R^6-X^2-Y^1-X^1-,

Y^1 is -O- or -NR^7-,

X^1 is a methylene group, an ethylene group (the methylene group and the ethylene group may be substituted with 1 to 2 methyl groups), a C_{3-8} cycloalkylene group, or a bond,

X^2 is a C_{1-4} alkylene group (the C_{1-4} alkylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below),

R^6 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, or a C_{1-6} alkoxy group,

R^7 is a hydrogen atom, a C_{1-6} alkyl group or a C_{3-8} cycloalkyl group (the C_{1-6} alkyl group and the C_{3-8} cycloalkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from the following group of substituents, R^c), and

the group of substituents, R^c, consists of a halogen atom, a hydroxy group, and a C_{1-6} alkyl group.

21. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 18, wherein

W is $Q\text{-}X^1\text{-}Y^2\text{-}X^3$-,

Y^2 is -O-, $-NR^7$-, or a bond,

X^1 is a C_{1-4} alkylene group (the C_{1-4} alkylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below), or a bond,

X^3 is a methylene group, an ethylene group (the methylene group and the ethylene group may be substituted with 1 to 2 methyl groups), a C_{3-8} cycloalkylene group, or a bond,

Q is a C_{3-8} cycloalkyl group, an aryl group, or a heterocyclic group (the C_{3-8} cycloalkyl group, the aryl group, or the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from the group of substituents, R^c, shown below

R^7 is a hydrogen atom, a C_{1-6} alkyl group or a C_{3-8} cycloalkyl group (the C_{1-6} alkyl group and the C_{3-8} cycloalkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from the following group of substituents, R^c), and

the group of substituents, R^c, consists of a halogen atom, a hydroxy group, a C_{1-6} alkyl group, a C_{1-6} hydroxyalkyl group, a C_{1-6} haloalkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (the C_{1-6} alkoxy group may be substituted with 1 to 3 hydroxy groups or halogen atoms), a C_{3-8} cycloalkoxy group, a C_{2-6} alkanoyl group, a C_{1-6} alkylidene group (the C_{1-6} alkylidene group may be substituted with a C_{1-6} alkoxy group), and a

hydroxyaminocarbonyl group.

22. The compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 18, wherein

W is a hydrogen atom, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, or a C_{1-6} alkylamino group (the C_{1-6} alkyl group, the C_{1-6} alkoxy group and the C_{1-6} alkylamino group may be substituted with 1 to 3 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, a C_{1-6} alkoxy group and a morpholino group").

23. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 22.

24. An LpxC inhibitor comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 23.

25. An antimicrobial agent comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 24.

the group of substituents, R^c, consists of a halogen atom, a hydroxy group, a cyano group, a nitro group, an amino group (the amino group may be substituted with a C_{2-6} alkanoyl group or one or two C_{1-6} alkyl groups), a carboxy group, a carbamoyl group, a ureido group, a guanidido group, a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with a heterocyclic group), a C_{1-6} hydroxyalkyl group, a C_{1-6} haloalkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (the C_{1-6} alkoxy group may be substituted with 1 to 3 hydroxy groups), a C_{3-8} cycloalkoxy group, a C_{1-6} alkoxycarbonyl group, a C_{1-6} alkoxycarbonylamino group, a C_{2-6} alkanoyl group, a C_{1-6} alkylsulfonyl group, a C_{1-6} alkylthio group, an aryl group, and a heterocyclic group (the aryl group and the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, a cyano group, a nitro group, an amino group, a carboxy group and a C_{1-6} alkyl group").

3. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein R^1 is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with the same or different 1 to 3 halogen atoms).

4. The compound or the pharmaceutically acceptable salt thereof, according to claim 3, wherein R^1 is a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with the same or different 1 to 3 halogen atoms).

5. The compound or the pharmaceutically acceptable salt thereof, according to claim 4, wherein R^1 is a methyl group.

6. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein R^2 is a hydrogen atom.

7. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein R^2 is a methyl group.

8. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein,

R^3 is a hydrogen atom, and

R^4 is a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with a phenyl group

or a monocyclic aromatic heterocyclic group (the phenyl group and the monocyclic aromatic heterocyclic group may be substituted with 1 to 3 substituents which are the same or different and are selected from "a halogen atom, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} haloalkyl group, a C_{1-6} hydroxyalkyl group, a C_{2-8} alkoxyalkyl group, a hydroxy group, a C_{1-6} alkoxy group, a C_{3-8} cycloalkoxy group, an amino group, a C_{1-6} alkylamino group, a di(C_{1-6} alkyl)amino group, -$N(R^{45})COR^{46}$, -$CON(R^{47})(R^{48})$")).

9. The compound or the pharmaceutically acceptable salt thereof, according to claim 8, wherein R^3 is a hydrogen atom, and R^4 is a methyl group.

10. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein A^1 is a phenylene group (the phenylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group").

11. The compound or the pharmaceutically acceptable salt thereof, according to claim 10, wherein A^1 is a phenylene group.

12. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein L is -C≡C-, -C≡C-C≡C-, -CH=CH-, -CH=CH-C≡C-, -C≡C-CH=CH-, an ethylene group, or a bond.

13. The compound or the pharmaceutically acceptable salt thereof, according to claim 12, wherein L is a bond or -C≡C-.

14. The compound or the pharmaceutically acceptable salt thereof, according to claim 13, wherein L is a bond.

15. The compound or the pharmaceutically acceptable salt thereof, according to claim 13, wherein L is -C≡C-.

16. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein

A^2 is a divalent aryl group (the divalent aryl group may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group"), a divalent monocyclic aromatic

fused ring heterocyclic group having a partially saturated monocycle, which is composed of a 5-membered ring and a 6-membered ring" (the phenylene group, the pyridinediyl group, the pyrimidinediyl group, the 2,4-furandiyl group, the pyrazolediyl group, the pyrrolediyl group, the "divalent fused ring aromatic heterocyclic group composed of a 5-membered ring and a 6-membered ring", and the "divalent fused ring heterocyclic group having a partially saturated monocycle, which is composed of a 5-membered ring and a 6-membered ring" may be substituted with 1 to 4 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, an amino group and a C_{1-6} alkyl group").

19. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein

W is R^6-X^1-,

X^1 is a methylene group or a bond,

R^6 is a hydrogen atom, an optionally protected hydroxy group, or R^8-ON=CR^9-,

R^8 is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below),

R^9 is a hydrogen atom, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, an amino group, or a C_{1-6} alkylamino group, and

the group of substituents, R^c, consists of a halogen atom and a hydroxy group.

20. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein

W is R^6-X^2-Y^1-X^1-,

Y^1 is -O- or -NR^7-,

X^1 is a methylene group, an ethylene group (the methylene group and the ethylene group may be substituted with 1 to 2 methyl groups), a C_{3-8} cycloalkylene group, or a bond,

X^2 is a C_{1-4} alkylene group (the C_{1-4} alkylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below),

R^6 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, or a C_{1-6} alkoxy group,

R^7 is a hydrogen atom, a C_{1-6} alkyl group or a C_{3-8} cycloalkyl group (the C_{1-6} alkyl group and the C_{3-8} cycloalkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from the following group of substituents, R^c), and

the group of substituents, R^c, consists of a halogen atom, a hydroxy group, and a C_{1-6} alkyl group.

21. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein

W is $Q\text{-}X^1\text{-}Y^2\text{-}X^3$-,

Y^2 is -O-, $-NR^7$-, or a bond,

X^1 is a C_{1-4} alkylene group (the C_{1-4} alkylene group may be substituted with 1 to 4 substituents which are the same or different and are selected from a group of substituents, R^c, to be shown below), or a bond,

X^3 is a methylene group, an ethylene group (the methylene group and the ethylene group may be substituted with 1 to 2 methyl groups), a C_{3-8} cycloalkylene group, or a bond,

Q is a C_{3-8} cycloalkyl group, an aryl group, or a heterocyclic group (the C_{3-8} cycloalkyl group, the aryl group, or the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from the group of substituents, R^c, shown below

R^7 is a hydrogen atom, a C_{1-6} alkyl group or a C_{3-8} cycloalkyl group (the C_{1-6} alkyl group and the C_{3-8} cycloalkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from the following group of substituents, R^c), and

the group of substituents, R^c, consists of a halogen atom, a hydroxy group, a C_{1-6} alkyl group, a C_{1-6} hydroxyalkyl group, a C_{1-6} haloalkyl group, a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (the C_{1-6} alkoxy group may be substituted with 1 to 3 hydroxy groups or halogen atoms), a C_{3-8} cycloalkoxy group, a C_{2-6} alkanoyl group, a C_{1-6} alkylidene group (the C_{1-6} alkylidene group may be substituted with a C_{1-6} alkoxy group), and a

hydroxyaminocarbonyl group.

22. The compound or the pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein

W is a hydrogen atom, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, or a C_{1-6} alkylamino group (the C_{1-6} alkyl group, the C_{1-6} alkoxy group and the C_{1-6} alkylamino group may be substituted with 1 to 3 substituents which are the same or different and are selected from "a halogen atom, a hydroxy group, a C_{1-6} alkoxy group and a morpholino group").

23. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2.

24. An LpxC inhibitor comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2.

25. An antimicrobial agent comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2.